SCHEMBL4396597

SCHEMBL4396597

CCN1CCCC1CC(NC(=O)Nc1ccc(F)c(F)c1)c1ccc(C(=O)Nc2ccccc2N)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 15/20 0.43
MCHR2 Q969V1 1/20 0.43
MCHR1 Q99705 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.41
HDAC2 Q92769 7/20 0.40
HDAC3 O15379 5/20 0.40
HDAC4 P56524 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
HDAC9 Q9UKV0 1/20 0.40
HDAC5 Q9UQL6 1/20 0.40
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NCOR2 Q9Y618 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4391490 0.88 MCHR2 (0.46) HDAC1MCHR2MCHR1L3MBTL1HDAC2
SCHEMBL2477594 0.88 HDAC1 (0.56) HDAC1MCHR2MCHR1L3MBTL1HDAC3
SCHEMBL2475221 0.85 CHRM3 (0.44) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL2474556 0.79 LMNA (0.47) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL2473804 0.79 HDAC1 (0.43) HDAC1MCHR2MCHR1L3MBTL1HDAC2
SCHEMBL4399758 0.77 LMNA (0.46) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL2476829 0.76 UTS2R (0.49) HDAC1HDAC2HDAC3MEN1LMNA
SCHEMBL4391410 0.72 HDAC1 (0.53) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL2476517 0.71 HDAC1 (0.51) HDAC1HDAC2HDAC3NCOR2
SCHEMBL2474090 0.71 UTS2R (0.52) HDAC1HDAC2HDAC3NCOR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 HDAC1 200/4885MCHR2 1349/4885MCHR1 2116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.